GB202010409D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB202010409D0 GB202010409D0 GBGB2010409.7A GB202010409A GB202010409D0 GB 202010409 D0 GB202010409 D0 GB 202010409D0 GB 202010409 A GB202010409 A GB 202010409A GB 202010409 D0 GB202010409 D0 GB 202010409D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010409.7A GB202010409D0 (en) | 2020-07-07 | 2020-07-07 | Pharmaceutical compounds |
| EP21746095.5A EP4178964A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
| PCT/GB2021/051731 WO2022008911A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
| BR112023000142A BR112023000142A2 (pt) | 2020-07-07 | 2021-07-07 | Derivados de benzodiazepina úteis no tratamento de infecção pelo vírus sincicial respiratório |
| CN202180053511.8A CN116075516B (zh) | 2020-07-07 | 2021-07-07 | 可用于治疗呼吸道合胞病毒感染的苯二氮杂䓬衍生物 |
| MX2023000440A MX2023000440A (es) | 2020-07-07 | 2021-07-07 | Derivados de benzodiacepinas útiles para el tratamiento de una infección del virus sincitial respiratorio. |
| KR1020237003865A KR20230035597A (ko) | 2020-07-07 | 2021-07-07 | 호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체 |
| JP2023501029A JP7840923B2 (ja) | 2020-07-07 | 2021-07-07 | 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体 |
| CA3188752A CA3188752A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
| US18/004,504 US20230270751A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010409.7A GB202010409D0 (en) | 2020-07-07 | 2020-07-07 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202010409D0 true GB202010409D0 (en) | 2020-08-19 |
Family
ID=72050502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2010409.7A Ceased GB202010409D0 (en) | 2020-07-07 | 2020-07-07 | Pharmaceutical compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230270751A1 (https=) |
| EP (1) | EP4178964A1 (https=) |
| JP (1) | JP7840923B2 (https=) |
| KR (1) | KR20230035597A (https=) |
| CN (1) | CN116075516B (https=) |
| BR (1) | BR112023000142A2 (https=) |
| CA (1) | CA3188752A1 (https=) |
| GB (1) | GB202010409D0 (https=) |
| MX (1) | MX2023000440A (https=) |
| WO (1) | WO2022008911A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202102602D0 (en) | 2021-02-24 | 2021-04-07 | Reviral Ltd | Pharmaceutical compounds |
| WO2024252355A1 (en) | 2023-06-08 | 2024-12-12 | Pfizer Inc. | Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv |
| WO2025120500A1 (en) | 2023-12-06 | 2025-06-12 | Pfizer Inc. | Benzodiazepine compounds as n-protein inhibitors |
| WO2025153942A1 (en) | 2024-01-16 | 2025-07-24 | Pfizer Inc. | Benzodiazepine pyrazolo carboxamides as n-protein inhibitors |
| CN121621343A (zh) * | 2026-02-02 | 2026-03-10 | 云南大学 | 一种化合物在防控植物病原真菌尖孢镰刀菌上的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5127096B2 (ja) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
| NZ538870A (en) | 2002-09-20 | 2007-04-27 | Arrow Therapeutics Ltd | Benzodiazepine derivatives and pharmaceutical compositions containing them |
| GB0406280D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Chemical compounds |
| WO2005090319A1 (en) | 2004-03-19 | 2005-09-29 | Arrow Therapeutics Limited | Process for preparing benzodiazepines |
| GB0406282D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| GB201506448D0 (en) | 2015-04-16 | 2015-06-03 | Univ Durham | An antimicrobial compound |
| DK3324977T3 (da) * | 2015-07-22 | 2022-10-17 | Enanta Pharm Inc | Benzodiazepinderivater som rsv-inhibitorer |
| GB201613942D0 (en) | 2016-08-15 | 2016-09-28 | Univ Of Durham The | An antimicrobial compound |
| US10398706B2 (en) * | 2017-01-06 | 2019-09-03 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as RSV inhibitors |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| KR101970214B1 (ko) * | 2017-07-17 | 2019-08-27 | 이화여자대학교 산학협력단 | 유기금속 화합물, 이들의 자기 조립체 및 이를 포함한 종양 진단 또는 치료용 조성물 |
| US10647711B2 (en) * | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915273D0 (en) | 2019-10-22 | 2019-12-04 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202010408D0 (en) | 2020-07-07 | 2020-08-19 | Reviral Ltd | Pharmaceutical compounds |
-
2020
- 2020-07-07 GB GBGB2010409.7A patent/GB202010409D0/en not_active Ceased
-
2021
- 2021-07-07 WO PCT/GB2021/051731 patent/WO2022008911A1/en not_active Ceased
- 2021-07-07 MX MX2023000440A patent/MX2023000440A/es unknown
- 2021-07-07 KR KR1020237003865A patent/KR20230035597A/ko active Pending
- 2021-07-07 EP EP21746095.5A patent/EP4178964A1/en active Pending
- 2021-07-07 JP JP2023501029A patent/JP7840923B2/ja active Active
- 2021-07-07 US US18/004,504 patent/US20230270751A1/en active Pending
- 2021-07-07 CN CN202180053511.8A patent/CN116075516B/zh active Active
- 2021-07-07 BR BR112023000142A patent/BR112023000142A2/pt unknown
- 2021-07-07 CA CA3188752A patent/CA3188752A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7840923B2 (ja) | 2026-04-06 |
| MX2023000440A (es) | 2023-04-13 |
| US20230270751A1 (en) | 2023-08-31 |
| CN116075516A (zh) | 2023-05-05 |
| EP4178964A1 (en) | 2023-05-17 |
| JP2023539985A (ja) | 2023-09-21 |
| BR112023000142A2 (pt) | 2023-01-31 |
| CN116075516B (zh) | 2026-02-03 |
| CA3188752A1 (en) | 2022-01-13 |
| KR20230035597A (ko) | 2023-03-14 |
| WO2022008911A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201911928D0 (en) | Pharmaceutical compounds | |
| IL276232A (en) | pharmaceutical compounds | |
| GB202020191D0 (en) | Pharmaceutical compounds | |
| GB202010409D0 (en) | Pharmaceutical compounds | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| GB202010408D0 (en) | Pharmaceutical compounds | |
| GB201810245D0 (en) | Pharmaceutical compounds | |
| GB201810239D0 (en) | Pharmaceutical compounds | |
| GB201819961D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| GB201819960D0 (en) | Pharmaceutical compounds | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| GB201801562D0 (en) | Pharmaceutical compounds | |
| GB202111193D0 (en) | Pharmaceutical compounds | |
| GB202200753D0 (en) | Pharmaceutical compounds | |
| GB202104097D0 (en) | Pharmaceutical compounds | |
| IL291570A (en) | Pharmaceutical preparations | |
| GB201800378D0 (en) | Pharmaceutical compounds | |
| GB202102602D0 (en) | Pharmaceutical compounds | |
| GB202201283D0 (en) | Pharmaceutical compounds | |
| GB201816369D0 (en) | Pharmaceutical compounds | |
| GB202213819D0 (en) | Pharmaceutical compound | |
| GB202117969D0 (en) | Pharmaceutical compounds | |
| GB202007163D0 (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |